Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with Type 2 diabetes mellitus

2005 ◽  
Vol 28 (5) ◽  
pp. 223-230 ◽  
Author(s):  
M. E. Garay-Sevilla ◽  
J. C. Regalado ◽  
J. M. Malacara ◽  
L. E. Nava ◽  
K. Wróbel-Zasada ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Advanced Glycosylation End Products ◽  
End Products ◽  
Advanced Glycosylation

Association of advanced glycation end products with peri-implant inflammation in prediabetes and type 2 diabetes mellitus patients

2018 ◽  
Vol 20 (4) ◽  
pp. 535-540 ◽  
Author(s):  
Mohammed Alrabiah ◽  
Khulud Abdulrahman Al-Aali ◽  
Zeyad H. Al-Sowygh ◽  
Abdulelah M. Binmahfooz ◽  
Sameer A Mokeem ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus

2019 ◽  
Vol 16 (5) ◽  
pp. 458-465 ◽  
Author(s):  
Eugenia Gkaliagkousi ◽  
Barbara Nikolaidou ◽  
Eleni Gavriilaki ◽  
Antonios Lazaridis ◽  
Efthalia Yiannaki ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Glycated Haemoglobin ◽  
Newly Diagnosed ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Aim: To investigate the thrombotic microenvironment in early stages of type 2 diabetes mellitus measuring platelet-derived, endothelial-derived and erythrocyte-derived microvesicles. Methods: We recruited 50 newly diagnosed type 2 diabetes mellitus patients who did not receive glucose-lowering treatment except for metformin and 25 matched non-type 2 diabetes mellitus volunteers. Microvesicles were measured with flow cytometry, glycated haemoglobin with high-performance liquid chromatography and advanced glycation end products with enzyme-linked immunosorbent assay. Results: Type 2 diabetes mellitus patients showed significantly higher levels of platelet-derived microvesicles [195/μL (115–409) vs 110/μL (73–150), p = 0.001] and erythrocyte-derived microvesicles [26/μL (9–100) vs 9/μL (4–25), p = 0.007] compared to non-type 2 diabetes mellitus individuals. Platelet-derived microvesicles were positively associated with fasting blood glucose ( p = 0.026) and glycated haemoglobin ( p = 0.002). Erythrocyte-derived microvesicles were also positively associated with fasting blood glucose ( p = 0.018) but not with glycated haemoglobin ( p = 0.193). No significant association was observed between platelet-derived microvesicles ( p = 0.126) or erythrocyte-derived microvesicles ( p = 0.857) and advanced glycation end products. Erythrocyte-derived microvesicles predicted the presence of type 2 diabetes mellitus, independently of platelet-derived microvesicles. Conclusion: In newly diagnosed type 2 diabetes mellitus, ongoing atherothrombosis is evident during the early stages as evidenced by increased microvesicles levels. Furthermore, the association with glycemic profile suggests that microvesicles represent not only a novel mechanism by which hyperglycemia amplifies thrombotic tendency in type 2 diabetes mellitus but also early markers of thrombosis highlighting the need for earlier management of hyperglycemia.

Risk factors and glycation end products in patients with different forms of coronary heart disease and type 2 diabetes mellitus

2015 ◽  
Vol 87 (10) ◽  
pp. 19
Author(s):  
E. V. Ivannikova ◽  
V. Yu. Kalashnikov ◽  
O. M. Smirnova ◽  
I. V. Kononenko ◽  
A. B. Kuznetsov ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Type 2 Diabetes Mellitus ◽  
Heart Disease ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document